Stem cells as delivery vehicles for oncolytic adenoviral virotherapy

Current Gene Therapy

Volumn 9, Issue 5, 2009, Pages 389-395

  Kranzler, Justin ^a   Tyler, Matthew A ^a   Sonabend, Adam M ^a   Ulasov, Ilya V ^a   Lesniak, Maciej S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Adenovirus; Brain cancer; Glioblastoma; Glioma; Mesenchymal stem cells; Neural stem cells; Stem cells; Virotherapy

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; CONDITIONALLY REPLICATING ADENOVIRUS; E1A PROTEIN; ONCOLYTIC ADENOVIRUS; ONCOLYTIC ADENOVIRUS DELTA 24 ARGINYLGLYCYLASPARTIC ACID; ONCOLYTIC VIRUS; ONYX 015; POLYLYSINE; SURVIVIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER GENE THERAPY; CELL FUNCTION; CLINICAL TRIAL; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG SPECIFICITY; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC MANIPULATION; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HUMAN; MESENCHYMAL STEM CELL; NEURAL STEM CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; RECURRENT CANCER; REVIEW; STEM CELL GENE THERAPY; TRANSGENE; TREATMENT RESPONSE; TUMOR CELL; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS STRAIN;

ADENOVIRIDAE; BRAIN NEOPLASMS; GENETIC VECTORS; GLIOBLASTOMA; HUMANS; ONCOLYTIC VIROTHERAPY; STEM CELLS;

ADENOVIRIDAE;

EID: 73449107485     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652309789753347     Document Type: Review

References (28)

1. Ehtesham M, Stevenson CB, Thompson RB. Stem cell therapies for malignant glioma. Neurosurg Focus 2005; 19: E5.
2. Lesniak MS, Brem H. Targeted therapy for brain tumours. Nat Rev Drug Discov 2004; 3: 499-508.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 10: 987-96.
4. Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 2004; 10: 5299-312.
5. Zheng S, Ulasov IV, Han Y,Tyler MA, Zhu ZB, Lesniak MS. Fiber knob modifications enhance adenoviral tropism and gene transfer in malignant glioma. J Gene Med 2007; 9: 151-60.
6. Sonabend AM, Ulasov IV, Lesniak MS. Gene therapy trials for the treatment of high grade gliomas. Gene Ther Mol Biol 2007; 11(A): 79-92.
7. Geoerger B, Grill J, Opolon P, et al. Oncolytic activity of the E1B-55kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res 2002; 62: 764-72.
8. Ulasov IV, Tyler M A, Rivera AA, Nettlebeck DM, Douglas JT, Lesniak MS. Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy. J Med Virol 2008; 80: 1595-603.
9. Chiocca EA, Abbed KM, Tatter S, et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1BAttenuated Adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas in the adjuvant setting. Mol Ther 2004; 10: 958-66.
10. Lemont JP, Nemunaitis J, Kuhn JA, Landers SA, McCarthy TM. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience.) Ann Surg Oncol 2000; 7: 588-92.
11. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001; 19: 289-98.
12. Vecil GG, Lang FF. Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses. J Neuro Oncol 2003; 65: 237-46.
13. Fueyo J, Jiang H, Gomez-Monzano C, et al. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst 2007; 99: 1410-4.
14. Altaner C. Glioblastoma and Stem Cells. Neoplasma 2008; 5: 369-74.
15. Ulasov IV, Zhu ZB, Tyler MA, et al. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther 2007; 18: 589-602.
16. Van Houdt WJ, Haviv YS, Lu B, et al. The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. J Neurosurg 2006; 104: 583-92.
17. Das A, Tan WL, Teo J, Smith RD. Expression of survivin in primary glioblastomas. J Cancer Res Clin Oncol 2002; 128: 302-6.
18. Aboody KS, Brown A, Rainov NG, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 2000; 97: 12846-51.
19. Aboody KS, Najbauer J, Danks MK. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther 2008; 15: 739-52.
20. Zhenggang Z, Quan J, Feng J, et al. In vivo magnetic resonance imaging tracks adult neural progenitor cell targeting of brain tumor. Neuroimage 2004; 23: 281-7.
21. Khalid S, Emilie B, Kim DE, et al. Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Ann Neurol 2005; 57: 34-41.
22. Tyler MA, Ulasov IV, Sonabend AM, et al. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther 2009; 16: 262-78.
23. Nakamizo A, Marini F, Amano T, et al. Human bone marrowderived medenchymal stem cells in the treatment of gliomas. Cancer Res 2005; 65: 3307-18.
24. Komarova S, Kawakami Y, Stoff-Khalili MA, Curiel DT, Pereboeva L. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 2006; 5: 755-66.
25. Sonabend AM, Ulasov IV, Tyler MA, Rivera AA, Mathis JM, Lesniak MS. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 2008; 26: 831-41.
26. Ehtesham M, Winston JA, Kabos P, Thompson, RC. CXCR4 expression mediates glioma cell invasiveness. Oncogene 2006; 25: 2801-6.
27. Ponte AL, Marais E, Gallay N, et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: Comparison of chemokine and growth factor chemotactic activities. Stem Cells 2007; 25: 1737-45.
28. Kim SU, Nakagawa E, Hatori K, Nagai A, Lee MA, Bang JH. Production of immortalized human neural crest stem cells. Methods Mol Biol 2002; 198: 55-65.